[go: up one dir, main page]

PA8532201A1 - Derivados de fenil cetonas sustituidas como antagonistas de ip - Google Patents

Derivados de fenil cetonas sustituidas como antagonistas de ip

Info

Publication number
PA8532201A1
PA8532201A1 PA20018532201A PA8532201A PA8532201A1 PA 8532201 A1 PA8532201 A1 PA 8532201A1 PA 20018532201 A PA20018532201 A PA 20018532201A PA 8532201 A PA8532201 A PA 8532201A PA 8532201 A1 PA8532201 A1 PA 8532201A1
Authority
PA
Panama
Prior art keywords
compounds
antagonists
fenyl
keton
receiver
Prior art date
Application number
PA20018532201A
Other languages
English (en)
Inventor
Alam Jahangir
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PA8532201A1 publication Critical patent/PA8532201A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • C07D233/50—Nitrogen atoms not forming part of a nitro radical with carbocyclic radicals directly attached to said nitrogen atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A COMPUESTOS QUE SON EN GENERAL MODULADORES DEL RECEPTOR DE IP, EN PARTICULAR ANTAGONISTAS DEL RECEPTOR DE IP, Y QUE ESTÁN REPRESENTADOS POR LA FORMULA GENERAL (I) EN DONDE A, R¹ Y R² SON COMO SE HA DEFINIDO EN LA ESPECIFICACIÓN; E ISÓMEROS INDIVIDUALES, MEZCLAS DE ISÓMEROS RACÉMICAS O NO-RACÉMICAS, Y SALES FARMACÉUTICAMENTE ACEPTABLES O SOLVATOS DE LOS MISMOS. LA INVENCIÓN SE REFIERE ADEMÁS A COMPOSICIONES FARMACÉUTICAS QUE CONTIENEN DICHOS COMPUESTOS, UN PROCESO PARA LA PREPARACIÓN DE DICHOS COMPUESTOS, Y SU USO PARA TRATAR ENFERMEDADES ASOCIADAS CON DOLOR, INFLAMACIÓN, ESTADOS PATOLÓGICOS DEL TRACTO URINARIO, ESTADOS PATOLÓGICOS RESPIRATORIOS, FORMACIÓN DE EDEMA, O ENFERMEDADES VASCULARES HIPOTENSIVAS.
PA20018532201A 2000-11-14 2001-11-13 Derivados de fenil cetonas sustituidas como antagonistas de ip PA8532201A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24888800P 2000-11-14 2000-11-14

Publications (1)

Publication Number Publication Date
PA8532201A1 true PA8532201A1 (es) 2002-08-26

Family

ID=22941114

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20018532201A PA8532201A1 (es) 2000-11-14 2001-11-13 Derivados de fenil cetonas sustituidas como antagonistas de ip

Country Status (29)

Country Link
EP (1) EP1339694B1 (es)
JP (1) JP4108474B2 (es)
KR (1) KR100562605B1 (es)
CN (1) CN1267423C (es)
AR (1) AR035502A1 (es)
AT (1) ATE305002T1 (es)
AU (1) AU2180802A (es)
BG (1) BG107814A (es)
BR (1) BR0115291A (es)
CA (1) CA2427900A1 (es)
CZ (1) CZ20031596A3 (es)
DE (1) DE60113563T2 (es)
EC (1) ECSP034602A (es)
ES (1) ES2248413T3 (es)
HU (1) HUP0303156A3 (es)
IL (1) IL155436A0 (es)
MA (1) MA26958A1 (es)
MX (1) MXPA03004073A (es)
NO (1) NO20032142D0 (es)
NZ (1) NZ525330A (es)
PA (1) PA8532201A1 (es)
PE (1) PE20020602A1 (es)
PL (1) PL362549A1 (es)
RU (1) RU2284995C2 (es)
SK (1) SK7222003A3 (es)
UY (1) UY27023A1 (es)
WO (1) WO2002040453A1 (es)
YU (1) YU37203A (es)
ZA (1) ZA200303413B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1596858A1 (en) * 2003-02-14 2005-11-23 Medical Research Council Ip receptor antagonists for the treatment of pathological uterine conditions
CN100372532C (zh) * 2003-05-01 2008-03-05 弗·哈夫曼-拉罗切有限公司 用作ip拮抗剂的咪唑啉-2-基氨基苯基酰胺
US20070060593A1 (en) * 2003-06-25 2007-03-15 Kerns Jeffrey K 4-Carboxamido quinoline derivatives for use as nk-2 and nk-3
RU2006103655A (ru) * 2003-07-09 2007-08-20 Ф.Хоффманн-Ля Рош Аг (Ch) Тиофениламиноимидазолины
CA2637292A1 (en) * 2006-01-27 2007-08-16 F. Hoffmann-La Roche Ag Use of 2-imidazoles for the treatment of cns disorders
CN101528710B (zh) 2006-10-19 2012-11-07 弗·哈夫曼-拉罗切有限公司 氨基甲基-4-咪唑类
EP2086959B1 (en) 2006-11-02 2011-11-16 F. Hoffmann-La Roche AG Substituted 2-imidazoles as modulators of the trace amine associated receptors
WO2008058867A2 (en) 2006-11-16 2008-05-22 F. Hoffmann-La Roche Ag Substituted 4-imidazoles
WO2008071574A1 (en) 2006-12-13 2008-06-19 F. Hoffmann-La Roche Ag Novel 2 -imidazoles as ligands for trace amine associated receptors (taar)
US20080146523A1 (en) 2006-12-18 2008-06-19 Guido Galley Imidazole derivatives
ES2510546T3 (es) 2007-02-02 2014-10-21 F. Hoffmann-La Roche Ag Nuevas 2-aminooxazolinas como ligandos TAAR1 para trastornos del SNC
AU2008214774A1 (en) 2007-02-15 2008-08-21 F. Hoffmann-La Roche Ag 2-aminooxazolines as TAAR1 ligands
KR101150561B1 (ko) 2007-07-02 2012-06-08 에프. 호프만-라 로슈 아게 미량 아민 결합 수용체(ｔａａｒ)에 대한 양호한 친화도를 갖는 2-이미다졸린
EP2173719A1 (en) 2007-07-03 2010-04-14 F. Hoffmann-Roche AG 4-imidazolines and their use as antidepressants
WO2009016048A1 (en) 2007-07-27 2009-02-05 F. Hoffmann-La Roche Ag 2-azetidinemethaneamines and 2-pyrrolidinemethaneamines as taar-ligands
JP5341084B2 (ja) 2007-08-03 2013-11-13 エフ．ホフマン−ラ ロシュ アーゲー Ｔａａｒ１リガンドとしてのピリジンカルボキシアミド及びベンズアミド誘導体
US8242153B2 (en) 2008-07-24 2012-08-14 Hoffmann-La Roche Inc. 4,5-dihydro-oxazol-2YL derivatives
US8354441B2 (en) 2009-11-11 2013-01-15 Hoffmann-La Roche Inc. Oxazoline derivatives
WO2011080132A2 (en) 2009-12-17 2011-07-07 Katholieke Universiteit Leuven, K.U. Leuven R&D Compounds, compositions and methods for controlling biofilms
US9452980B2 (en) 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
US9321745B2 (en) 2013-03-12 2016-04-26 Allergan, Inc. Inhibition of neovascularization by inhibition of prostanoid IP receptors
US9295665B2 (en) 2013-03-12 2016-03-29 Allergan, Inc. Inhibition of neovascularization by simultaneous inhibition of prostanoid IP and EP4 receptors
US9827225B2 (en) * 2016-01-25 2017-11-28 Jenivision Inc. Use of prostacyclin antagonists for treating ocular surface nociception
CN108713019B (zh) 2016-03-17 2021-06-15 豪夫迈·罗氏有限公司 具有作为taar的激动剂的活性的5-乙基-4-甲基-吡唑-3-甲酰胺衍生物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4889868A (en) * 1984-12-20 1989-12-26 Rorer Pharmaceutical Corporation Bis-imidazolinoamino derivatives as antiallergy compounds
GB9506188D0 (en) * 1995-03-27 1995-05-17 Fujisawa Pharmaceutical Co Amidine derivatives
NZ331480A (en) * 1997-09-04 2000-02-28 F 2-(Arylphenyl)amino-imidazoline derivatives and pharmaceutical compositions

Also Published As

Publication number Publication date
ES2248413T3 (es) 2006-03-16
CN1474813A (zh) 2004-02-11
KR20030065512A (ko) 2003-08-06
CN1267423C (zh) 2006-08-02
AU2180802A (en) 2002-05-27
HUP0303156A3 (en) 2004-03-29
NO20032142L (no) 2003-05-13
BR0115291A (pt) 2003-08-19
PL362549A1 (en) 2004-11-02
AR035502A1 (es) 2004-06-02
JP2004513940A (ja) 2004-05-13
EP1339694B1 (en) 2005-09-21
ATE305002T1 (de) 2005-10-15
NO20032142D0 (no) 2003-05-13
PE20020602A1 (es) 2002-07-08
DE60113563D1 (de) 2006-02-02
YU37203A (sh) 2006-05-25
IL155436A0 (en) 2003-11-23
HUP0303156A2 (hu) 2004-01-28
EP1339694A1 (en) 2003-09-03
ZA200303413B (en) 2004-08-02
ECSP034602A (es) 2003-06-25
MXPA03004073A (es) 2003-09-04
SK7222003A3 (en) 2004-05-04
NZ525330A (en) 2004-10-29
JP4108474B2 (ja) 2008-06-25
WO2002040453A1 (en) 2002-05-23
MA26958A1 (fr) 2004-12-20
BG107814A (bg) 2004-02-27
DE60113563T2 (de) 2006-07-13
CZ20031596A3 (cs) 2004-01-14
CA2427900A1 (en) 2002-05-23
RU2284995C2 (ru) 2006-10-10
KR100562605B1 (ko) 2006-03-17
UY27023A1 (es) 2002-06-20

Similar Documents

Publication Publication Date Title
PA8532201A1 (es) Derivados de fenil cetonas sustituidas como antagonistas de ip
HN1999000124A (es) Derivados de pirazol substituido.
HN1999000149A (es) Derivados de 4,4-biarilpiperidina
CR9834A (es) [1,8]naftiridin-2-onas y compuestos relacionados para el tratamiento de la ezquizofrenia
MX9300298A (es) Conjugados de tioeter y procedimiento para su preparacion
PA8547901A1 (es) Derivados de 4-piperacinilindol con afinidad receptora de 5-ht6
SV2002000249A (es) Derivados de tiazolilamida ref, lea 34082-sv
PA8577001A1 (es) Benzoilureas heterociclicamente sustituidas, procedimiento para su preparacion y su uso como farmacos
PA8546601A1 (es) Nuevos derivados de indol con afinidad por el receptor 5-ht6
ES2178676T3 (es) Compuestos de pirimidina substituidos y su empleo.
UY26974A1 (es) Agonistas del receptor beta3 adrenérgico y usos de los mismos
AR006119A1 (es) Compuestos de quinoxalinadionas uso de los mismos para la fabricacion de un medicamento, compuestos de quinoxalinas para producirlos y procedimiento parala preparacion de los mismos
AR002268A1 (es) Antagonistas de vasopresina de benzacepina triciclicos, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso dedichos compuestos para preparar composiciones farmaceuticas.
UY26199A1 (es) Nuevos derivados de benceno, un procedimiento para su preparación y las composiciones farmacéuticas que los contienen
ES2194918T3 (es) Compuestos de tiazol y tiadiazol como ligando receptor de dopamina d3.
UY26728A1 (es) Derivados de la benzocicloalquilenilamina como antagonistas de los receptores muscarínicos
CL2003002769A1 (es) Compuestos derivados de carboxamida de tiazolilpirrol; procedimiento para su preparacion; composiciones farmaceuticas que los comprenden; y su uso para el tratamiento y/o profilaxis de enfermedades asociadas con la modulacion de receptores canabinoid
AR028624A1 (es) Heterociclilalquilaminas como antagonistas de receptores muscarinicos
UY26919A1 (es) Derivados de la quinazolina como antagonistas adrenérgicos alfa - 1
BR0215222A (pt) Derivados de indolilalquilamina como ligantes de 5-hidroxitriptamina-6
PA8527401A1 (es) 7-oxo-piridopirimidinas (ii)
ES2172937T3 (es) 21-hidroxi-6,19-oxidoprogesterona(21oh-6op) como medicamento para tratar el exceso de glucocorticoides.
NI200700030A (es) Moduladores tricíclicos del delta-opioide
BRPI0415203A (pt) pentanóis reestruturados, um processo para sua produção e seu uso como agentes antiinflamatórios
ES2171911T3 (es) Poliaminas conformacionalmente restringidas y su uso como agentes antineoplasicos.